the lowest level of PSA achieved after completion of radiation, is a determinant of outcomes, and we have previously shown that a nPSA of 0.06 ng/mL is a strong independent predictor of biochemical recurrence-free survival (bRFS) in patients with intermediate-risk (IR) or HR prostate cancer treated by definitive EBRT and ADT [16]. This evidence concerns the gene KLK3 and prostate carcinoma.